| Autor: |
Alonso-Alonso R; Pathology Department Lymphoma Unit, Department of Hematology.; Center for Biomedical Network on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Rodríguez M; Pathology Department Lymphoma Unit, Department of Hematology.; Center for Biomedical Network on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain., García-Díaz N; Molecular Biology Department, University of Cantabria, Infection, Immunity & Digestive Pathology, Instituto de Investigación Sanitaria Marqués de Valdecilla (IDIVAL), Santander, Spain., Tomás-Roca L; Pathology Department Lymphoma Unit, Department of Hematology., Borregón J; Pathology Department Lymphoma Unit, Department of Hematology., Cabezuelo-Rodríguez M; Pathology Department Lymphoma Unit, Department of Hematology., Rebollo-González M; Pathology Department Lymphoma Unit, Department of Hematology., Gallego-Manzano L; Pathology Department Lymphoma Unit, Department of Hematology., Cereceda L; Pathology Department Lymphoma Unit, Department of Hematology.; Center for Biomedical Network on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Rodriguez-Pinilla SM; Pathology Department Lymphoma Unit, Department of Hematology.; Center for Biomedical Network on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Córdoba R; Center for Biomedical Network on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Fernando García J; Pathology Department, Hospital MD Anderson Cancer Center, Madrid, Spain., Torre-Castro J; Dermatology Department; Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain., García-Álvarez CM; Dermatology., Del Mar Onteniente Gomis M; Dermatology., Rivera-Díaz R; Dermatology., Rodriguez-Peralto JL; Center for Biomedical Network on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Pathology Departments, Hospital Universitario 12 de Octubre, Madrid, Spain., Vaqué JP; Molecular Biology Department, University of Cantabria, Infection, Immunity & Digestive Pathology, Instituto de Investigación Sanitaria Marqués de Valdecilla (IDIVAL), Santander, Spain., Ortiz-Romero PL; Center for Biomedical Network on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Dermatology., Piris MÁ; Pathology Department Lymphoma Unit, Department of Hematology.; Center for Biomedical Network on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. |
| Abstrakt: |
Competing Interests: Conflicts of interest M.A.P. declares having received lecture fees and advisory board fees from Celgene, Gilead, Jansen, Kyowa Kirin, Millenium/Takeda and NanoString. P.L.O.-R. declares having received advisory fees from 4SC, Helsinn, Innate Pharma, Kyowa Kirin, Mallinckrodt, Recordati Rare Diseases and Takeda. The authors declare that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. |
